Aurinia to Participate in Jefferies London Healthcare Conference

About this update from Aurinia Pharmaceuticals Inc

ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London , November 19-21, 2024 . Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20 , at 12:00 PM GMT / 7:00 AM EST . This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). View source version on businesswire.com : https://www.businesswire.com/news/home/20241114401812/en/ Media & Investor Inquiries: Andrea Christopher Corporate Communications & Investor Relations Aurinia Pharmaceuticals Inc. [email protected] General Investor Inquiries: [email protected] Source: Aurinia Pharmaceuticals Inc.

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc